Saturday July 4, 2020

Elan reports loss, in talks with many companies

UPDATE: Biotechnology company Elan posted a net operating loss of $72.8 million for the first quarter of 2013.

24th April, 2013
Elan

Biotechnology company Elan posted a net operating loss of $72.8 million for the first quarter of 2013, down from $74.7 million in the comparable period last year.

The company said that first quarter global sales of the MS drug Tysabri increased by 14 per cent to €456 million.

Elan recently completed the sale of its stake in Tysabri and said it now has about $2 billion in cash and cash equivalents as a result.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 6 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago